(AHR) American Healthcare REIT - Overview
Sector: Real Estate | Industry: REIT - Healthcare Facilities | Exchange: NYSE (USA) | Market Cap: 9.673m USD | Total Return: 42.8% in 12m
Avg Turnover: 135M
Qual. Beats: 0
Rev. Trend: 99.7%
Qual. Beats: -1
Warnings
P/E ratio 85.1
Share dilution 19.8% YoY
Beneish M-Score 1.00 > -1.5 - likely earnings manipulation
Altman Z'' -1.30 < 1.0 - financial distress zone
Below Avwap Earnings
Tailwinds
No distinct edge detected
American Healthcare REIT, Inc. (NYSE: AHR) is a self-managed real estate investment trust that owns and operates a diversified clinical healthcare portfolio across the United States, the United Kingdom, and the Isle of Man. The company’s core holdings include senior housing, skilled nursing facilities, and outpatient medical buildings.
The company utilizes a RIDEA (REIT Investment Quality Act) structure for its senior housing operations, which allows the REIT to participate in the underlying operating cash flows of the properties rather than solely collecting fixed rent. This model provides higher exposure to the operational upside of the healthcare sector but also carries greater exposure to fluctuations in labor costs and occupancy rates.
In addition to property ownership, AHR engages in real estate-related investments such as secured loans and selective property development. To maintain its REIT status under the U.S. Internal Revenue Code, the company must distribute at least 90% of its taxable income to shareholders annually.
Investors can further analyze these operational structures and financial metrics by visiting ValueRay. Detailed due diligence remains essential when evaluating the long-term impact of demographic shifts on healthcare real estate demand.
- Occupancy recovery and rate growth in senior housing operating portfolios drive margins
- Integrated RIDEA structure exposes earnings to direct property-level operational performance and risks
- Medicare and Medicaid reimbursement policy changes impact skilled nursing facility rental coverage
- Interest rate fluctuations influence cost of capital and future property acquisition yields
- Aging demographic trends sustain long-term demand for clinical and outpatient medical real estate
| Net Income: 100.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.00 > 0.02 and ΔFCF/TA -3.34 > 1.0 |
| NWC/Revenue: 15.2k% < 20% (prev 6.09%; Δ 15.2k% < -1%) |
| CFO/TA 0.00 > 3% & CFO 321.9m > Net Income 100.3m |
| Current Ratio: 405.6 > 1.5 & < 3 |
| Outstanding Shares: last quarter (188.0m) vs 12m ago 19.79% < -2% |
| Gross Margin: 9.57% > 18% (prev 0.20%; Δ 936.7% > 0.5%) |
| Asset Turnover: 0.08% > 50% (prev 47.31%; Δ -47.22% > 0%) |
| Interest Coverage Ratio: 1.71 > 6 (EBITDA TTM 362.5m / Interest Expense TTM 81.6m) |
| A: 0.06 (Total Current Assets 361b - Total Current Liabilities 890.1m) / Total Assets 5599b |
| B: -0.28 (Retained Earnings -1583b / Total Assets 5599b) |
| C: 0.00 (EBIT TTM 139.6m / Avg Total Assets 2802b) |
| D: -0.76 (Book Value of Equity -1584b / Total Liabilities 2077b) |
| Altman-Z'' = -1.30 = CCC |
| DSRI: 794.1 (Receivables 242b/271.1m, Revenue 2.37b/2.11b) |
| GMI: 2.12 (GM 9.57% / 20.32%) |
| AQI: 7.66 (AQ_t 0.89 / AQ_t-1 0.12) |
| SGI: 1.12 (Revenue 2.37b / 2.11b) |
| TATA: -0.00 (NI 100.3m - CFO 321.9m) / TA 5599b) |
| Beneish M = 654.7 (Cap -4..+1) = D |
As of June 02, 2026, the stock is trading at USD 47.23 with a total of 1,315,603 shares traded.
Over the past week, the price has changed by -2.47%,
over one month by -3.72%,
over three months by -7.09% and
over the past year by +42.81%.
American Healthcare REIT has received a consensus analysts rating of 4.33. Therefore, it is recommended to buy AHR.
- StrongBuy: 4
- Buy: 4
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 58.6 | 24.1% |
P/E Trailing = 85.0678
P/E Forward = 61.7284
P/S = 4.0797
P/B = 2.7782
Revenue TTM = 2.37b USD
EBIT TTM = 139.6m USD
EBITDA TTM = 362.5m USD
Long Term Debt = 996.0m USD (from longTermDebt, last quarter)
Short Term Debt = 549.8m USD (from shortLongTermDebt, last quarter)
Debt = 1.68b USD (from shortLongTermDebtTotal, last quarter) + Leases 130.8m
Net Debt = -118b USD (calculated: Debt 1.68b - CCE 119b)
Enterprise Value = 9.67b USD (floored to Market Cap, CCE > MCap+Debt)
Interest Coverage Ratio = 1.71 (Ebit TTM 139.6m / Interest Expense TTM 81.6m)
EV/FCF = 41.07x (Enterprise Value 9.67b / FCF TTM 235.5m)
FCF Yield = 2.43% (FCF TTM 235.5m / Enterprise Value 9.67b)
FCF Margin = 9.94% (FCF TTM 235.5m / Revenue TTM 2.37b)
Net Margin = 4.23% (Net Income TTM 100.3m / Revenue TTM 2.37b)
Gross Margin = 9.57% ((Revenue TTM 2.37b - Cost of Revenue TTM 2.14b) / Revenue TTM)
Gross Margin QoQ = -1.32% (prev 0.14%)
Tobins Q-Ratio = 0.00 (Enterprise Value 9.67b / Total Assets 5599b)
Interest Expense / Debt = 4.86% (Interest Expense 81.6m / Debt 1.68b)
Taxrate = 21.0% (US default 21%)
NOPAT = 110.3m (EBIT 139.6m * (1 - 21.00%))
Current Ratio = 405.6 (out of range, set to none) (Total Current Assets 361b / Total Current Liabilities 890.1m)
Debt / Equity = 0.00 (Debt 1.68b / totalStockholderEquity, last quarter 3482b)
Debt / EBITDA = -324.7 (out of range, set to none) (Net Debt -118b / EBITDA 362.5m)
Debt / FCF = -499.8 (out of range, set to none) (Net Debt -118b / FCF TTM 235.5m)
Total Stockholder Equity = 873b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.00% (Net Income 100.3m / Total Assets 5599b)
RoE = 0.00% (Net Income TTM 100.3m / Total Stockholder Equity 2456b)
RoCE = 0.01% (EBIT 139.6m / Capital Employed (Equity 2456b + L.T.Debt 996.0m))
RoIC = 0.00% (NOPAT 110.3m / Invested Capital 5598b)
WACC = 6.64% (E(9.67b)/V(11.4b) * Re(7.13%) + D(1.68b)/V(11.4b) * Rd(4.86%) * (1-Tc(0.21)))
Discount Rate = 7.13% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 59.18%
[DCF] Terminal Value 77.97% ; FCFF base≈201.1m ; Y1≈230.5m ; Y5≈339.2m
[DCF] Fair Price = 637.2 (EV 5.10b - Net Debt -118b = Equity 123b / Shares 192.7m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.08 | # QB: 0
Revenue Correlation: 99.69 | Revenue CAGR: 10.43% | SUE: -1.76 | # QB: -1
EPS current Quarter (2026-06-30): EPS=0.13 | Chg30d=-27.78% | Revisions=-20% | Analysts=1
EPS next Quarter (2026-09-30): EPS=0.15 | Chg30d=-23.74% | Revisions=-20% | Analysts=1
EPS current Year (2026-12-31): EPS=0.55 | Chg30d=-25.34% | Revisions=-20% | GrowthEPS=-19.3% | GrowthRev=+18.9%
EPS next Year (2027-12-31): EPS=0.82 | Chg30d=-16.04% | Revisions=-33% | GrowthEPS=+49.1% | GrowthRev=+10.7%